• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测 2019 年冠状病毒病住院患者疾病严重程度的因素。

Predictors of disease severity in patients hospitalized with coronavirus disease 2019.

机构信息

From the Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

From the Department of Biostatistics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

出版信息

Ann Saudi Med. 2023 Jul-Aug;43(4):254-261. doi: 10.5144/0256-4947.2023.254. Epub 2023 Aug 3.

DOI:10.5144/0256-4947.2023.254
PMID:37554023
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10716835/
Abstract

BACKGROUND

Coronavirus disease 2019 (COVID-19), caused by a novel coronavirus, manifests as a respiratory illness primarily and symptoms range from asymptomatic to severe respiratory syndrome and even death. During the pandemic, due to overcrowding of medical facilities, clinical assessment to triage patients for home care or in-hospital treatment was an essential element of management.

OBJECTIVES

Study the demographic features, comorbidities and bio-markers that predict severe illness and mortality from COVID-19 infection.

DESIGN

Retrospective observational SETTING: Single tertiary care center PATIENTS AND METHODS: The study included all patients admitted with a positive PCR test for COVID-19 during the period from March 2020 to September 2020 (7 months). Data on demographics, clinical data and laboratory parameters was collected from medical records every 3 days during hospital stay or up until transfer to ICU.

MAIN OUTCOME MEASURES

Demographic, comorbidities and biochemical features that might predict severe COVID-19 disease.

SAMPLE SIZE

372 RESULTS: Of the 372 patients, 72 (19.4%) had severe disease requiring admission to intensive care unit (ICU); 6 (1.6%) died. Individuals over 62 years were more likely to be admitted to the ICU (=.0001, while a BMI of 40 and higher increased the odds of severe disease (=.032). Male gender (=.042), hypertension (=.006) and diabetes (=.001) conferred a statistically significant increased risk of admission to ICU, while coexisting COPD, and ischemic heart disease did not. Laboratory features related to severe COVID-19 infection were: leukocytosis (=.015), thrombocytopenia (=.001), high levels of C-reactive protein (=.0001), lactic dehydrogenase (=.0001), D-dimer (=.0001) and ferritin (=.001). With the multivariate analysis, diabetes, high lac-tate dehydrogenase, C-reactive protein and thrombocytopenia were associated with severity of illness.

CONCLUSIONS

Particular demographic and clinical parameters may predict severe illness and need for ICU care.

LIMITATIONS

Single referral center, several cases of severe COVID-19 could not be included due to lack of consent and or data.

CONFLICT OF INTEREST

None.

摘要

背景

由新型冠状病毒引起的 2019 年冠状病毒病(COVID-19)主要表现为呼吸道疾病,症状从无症状到严重呼吸综合征甚至死亡不等。在大流行期间,由于医疗设施拥挤,对患者进行临床评估以分流到家庭护理或住院治疗是管理的重要组成部分。

目的

研究预测 COVID-19 感染严重疾病和死亡的人口统计学特征、合并症和生物标志物。

设计

回顾性观察性研究

地点

单一体三叶式关怀中心

患者和方法

该研究纳入了 2020 年 3 月至 2020 年 9 月(7 个月)期间因 COVID-19 阳性 PCR 检测而住院的所有患者。从病历中收集住院期间每 3 天的人口统计学、临床数据和实验室参数,或直至转移至 ICU。

主要观察指标

可能预测严重 COVID-19 疾病的人口统计学、合并症和生化特征。

样本量

372

结果

在 372 名患者中,有 72 名(19.4%)患有需要入住重症监护病房(ICU)的严重疾病;有 6 名(1.6%)死亡。62 岁以上的患者更有可能被收入 ICU(<.0001),而 BMI 为 40 及以上则增加严重疾病的几率(=.032)。男性(=.042)、高血压(=.006)和糖尿病(=.001)使 ICU 入院的风险具有统计学意义的增加,而同时患有 COPD 和缺血性心脏病则没有。与严重 COVID-19 感染相关的实验室特征包括:白细胞增多(=.015)、血小板减少症(=.001)、C 反应蛋白水平升高(=.0001)、乳酸脱氢酶升高(=.0001)、D-二聚体升高(=.0001)和铁蛋白升高(=.001)。在多变量分析中,糖尿病、高乳酸脱氢酶、C 反应蛋白和血小板减少症与疾病严重程度相关。

结论

特定的人口统计学和临床参数可能预测严重疾病和对 ICU 护理的需求。

局限性

单一转诊中心,由于缺乏同意和/或数据,无法纳入几例严重 COVID-19 病例。

利益冲突

无。

相似文献

1
Predictors of disease severity in patients hospitalized with coronavirus disease 2019.预测 2019 年冠状病毒病住院患者疾病严重程度的因素。
Ann Saudi Med. 2023 Jul-Aug;43(4):254-261. doi: 10.5144/0256-4947.2023.254. Epub 2023 Aug 3.
2
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
3
Predictors of Severity in Covid-19 Patients in Casablanca, Morocco.摩洛哥卡萨布兰卡新冠肺炎患者严重程度的预测因素
Cureus. 2020 Sep 29;12(9):e10716. doi: 10.7759/cureus.10716.
4
Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.风湿性疾病患者 COVID-19 疾病严重程度的决定因素。
Clin Rheumatol. 2020 Sep;39(9):2789-2796. doi: 10.1007/s10067-020-05301-2. Epub 2020 Jul 27.
5
A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial.一项评估 ICU 收治的 COVID-19 患者静脉用褪黑素的疗效和安全性的 II 期、单中心、双盲、随机安慰剂对照试验(MelCOVID 研究):一项随机对照试验研究方案的结构摘要。
Trials. 2020 Aug 5;21(1):699. doi: 10.1186/s13063-020-04632-4.
6
Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia.Meta 分析研究严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)肺炎的临床特征、结局和严重程度之间的关系。
Am J Infect Control. 2021 Jan;49(1):82-89. doi: 10.1016/j.ajic.2020.06.008. Epub 2020 Jun 12.
7
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
8
Pregnant women with severe or critical coronavirus disease 2019 have increased composite morbidity compared with nonpregnant matched controls.患有严重或危急 2019 冠状病毒病的孕妇与未怀孕的匹配对照相比,复合发病率增加。
Am J Obstet Gynecol. 2021 May;224(5):510.e1-510.e12. doi: 10.1016/j.ajog.2020.11.022. Epub 2020 Nov 20.
9
Characteristics and outcomes of critically ill patients with covid-19 in Sakarya, Turkey: a single centre cohort study.土耳其萨卡里亚市新冠肺炎危重症患者的特征和结局:一项单中心队列研究。
Turk J Med Sci. 2021 Apr 30;51(2):440-447. doi: 10.3906/sag-2005-57.
10
Sex disparities in COVID-19 outcomes of inpatients with diabetes: insights from the CORONADO study.COVID-19 住院糖尿病患者结局的性别差异:来自 CORONADO 研究的启示。
Eur J Endocrinol. 2021 Jul 5;185(2):299-311. doi: 10.1530/EJE-21-0068.

本文引用的文献

1
Outcomes of Heart Failure Related Hospitalizations During the COVID-19 Pandemic.新冠疫情期间心力衰竭相关住院治疗的结果
Cureus. 2023 Mar 30;15(3):e36935. doi: 10.7759/cureus.36935. eCollection 2023 Mar.
2
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)的全球流行病学:系统评价。
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.
3
Global incidence and prevalence of nonalcoholic fatty liver disease.全球非酒精性脂肪性肝病的发病率和患病率。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S32-S42. doi: 10.3350/cmh.2022.0365. Epub 2022 Dec 14.
4
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦片/利托那韦片组合包装用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2.
5
Uptake of COVID-19 Booster Dose among Saudi Arabian Population.沙特阿拉伯人口对 COVID-19 加强针的接种情况。
Medicina (Kaunas). 2022 Jul 21;58(7):972. doi: 10.3390/medicina58070972.
6
Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series - 465 Health Care Facilities, United States, December 2020-October 2021.≥18 岁完成初级 COVID-19 疫苗接种系列的人群中严重 COVID-19 结局的危险因素-465 家医疗保健机构,美国,2020 年 12 月-2021 年 10 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 7;71(1):19-25. doi: 10.15585/mmwr.mm7101a4.
7
Impact of COVID-19 on liver.新型冠状病毒肺炎对肝脏的影响。
World J Clin Cases. 2021 Sep 26;9(27):7998-8007. doi: 10.12998/wjcc.v9.i27.7998.
8
Lymphopenia Caused by Virus Infections and the Mechanisms Beyond.病毒感染引起的淋巴细胞减少症及其机制。
Viruses. 2021 Sep 20;13(9):1876. doi: 10.3390/v13091876.
9
Impact of rituximab on COVID-19 outcomes.利妥昔单抗对 COVID-19 结局的影响。
Ann Hematol. 2021 Nov;100(11):2805-2812. doi: 10.1007/s00277-021-04662-1. Epub 2021 Sep 22.
10
The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis.COVID-19 对妊娠结局的影响:系统评价和荟萃分析。
CMAJ. 2021 Apr 19;193(16):E540-E548. doi: 10.1503/cmaj.202604. Epub 2021 Mar 19.